Cornea News and Research

RSS

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

20 Aug 2009

Gene Signal publishes phase I data on GS-101 for diseases of the eye

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, has announced publication of data from a phase I study demonstrating that the antisense oligonucleotide GS-101 (eye drops) is safe, with no signs of intolerability following administration to healthy volunteers.

11 Aug 2009

New molecule blocks lymphangiogenesis

Researchers in the laboratory of Dr. Jayakrishna Ambati at the University of Kentucky have discovered the first naturally occurring molecule that selectively blocks lymphatic vessel growth. In an article in the Aug. 9, 2009 online edition of Nature Medicine, they report the identification of a new molecule known as soluble VEGFR-2 that blocks lymphangiogenesis - the growth of lymphatics - but not blood vessel growth.

11 Aug 2009

Factors linked to failure of corneal transplants

Certain eye conditions appear to put patients at greater risk for having a failed cornea transplant, according the Cornea Donor Study (CDS), a multi-center clinical trial conducted by the National Eye Institute. The study concludes that patients with glaucoma and patients who had corneal swelling following an earlier cataract surgery were more likely to experience failure of the cornea transplant than were other patients in the study.

11 Jun 2009

Light therapy as a treatment for sexual dysfunctions

Although we are still far from knowing exactly where and how the pineal suppressive role is exerted, the fact that the gland exerts an inhibitory function on the reproductive axis is widely accepted. In fact, the pineal seems to exert its hormonal effect at different levels of the reproductive axis, both at the hypothalamic-pituitary level and at the gonadal level, where melatonin receptors have also been found.

9 Jun 2009

New surgical tool for complicated eye surgery

Eye surgeons will soon have a new surgical tool to help make a complicated eye surgery less labor intensive while providing significant advantages for corneal transplant patients, as a result of an invention by a Wake Forest University Baptist Medical Center physician.

28 May 2009

Simple stem cell technique restores sight to damaged eyes

In a world-first breakthrough by Australian scientists, the eyesight in a damaged eye has been restored by using stem cells from the eye itself

27 May 2009

Stem cell breakthrough restores sight to sufferers of corneal disease

In a world-first breakthrough, University of New South Wales (UNSW) medical researchers have used stem cells cultured on a simple contact lens to restore sight to sufferers of blinding corneal disease.

27 May 2009

Topical bevacizumab therapy effective in treating corneal blood vessels growth that can cause blindness

Researchers at the Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute have concluded that short-term topical bevacizumab therapy reduces the severity of corneal neovascularization (formation of new blood vessels in the cornea that can create impaired vision or vision loss) without local or systemic adverse effects.

15 Apr 2009

Stem cell therapy used to restore transparency in corneas

Stem cells collected from human corneas restore transparency and don't trigger a rejection response when injected into eyes that are scarred and hazy, according to experiments conducted in mice by researchers at the University of Pittsburgh School of Medicine.

12 Apr 2009

Two new hereditary corneal disorders discovered

Two new disorders affecting the cornea have been discovered by researchers at Linkoping University. The hereditary disorders were discovered in two Swedish families.

7 Apr 2009

Sirion Therapeutics sNDA for Durezol to treat uveitis accepted for FDA review

Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.

16 Mar 2009

Chili Peppers continue to help unravel mechanism of pain sensation

Capsaicin, the active ingredient in chili peppers, generally is viewed as an irritant that produces a burning sensation when applied to a sensitive area of the body, such as the cornea.

25 Feb 2009

Gene-targeting approach for herpes treatment

A new therapy being developed at the University of Florida could, in time, produce another weapon for the fight against herpes.

3 Feb 2009

FDA announces recall of ophthalmic viscosurgical device

The U.S. Food and Drug Administration announced a Class I recall of lot no. UD30654 of Healon D, an ophthalmic viscosurgical device (OVD) manufactured by Advanced Medical Optics Inc. (AMO) of Santa Ana, Calif.

5 Jan 2009

Study evaluates corneal collagen cross-linking in subjects with progressive keratoconus

Presently keratoconus is treated through eyeglasses, hard contact lenses, and a newer treatment, INTACS plastic rings inserted into the mid layer of the cornea to flatten it, changing the shape and location of the cone.

26 Nov 2008

Advances in ophthalmology

The 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE), the largest and most comprehensive ophthalmic educational meeting in the world, is in session November 8 to 11 at the Georgia World Congress Center, Atlanta.

10 Nov 2008